To date, no consistency exists across studies that have evaluated the relationship between hepatic lipase gene (LIPC) rs10468017 variant and advanced age-related macular degeneration (AMD).
A ge-related macular degeneration (AMD) is a progressive disease of the central retina and a leading cause of irreversible blindness for older individuals worldwide. 1 Most vision loss occurs when AMD progresses to 1 of 2 advanced forms, namely, choroidal neovascularization (CNV [wet AMD]) and geographic atrophy (GA [dry AMD]). It has been estimated that cases of advanced AMD will increase from 1.7 million in 2010 to 3.8 million in 2050 based on the findings of a 2009 study. 2 Age-related macular degeneration is a multifactorial disease that involves complex interactions between environmental and genetic factors. Several environmental risk factors have been identified, including cigarette smoking, higher body mass index, and insufficient dietary antioxidants. [3] [4] [5] Compelling evidence also exists for the contribution of genetic factors to the incidence and progression of AMD. 6 Multiple genetic variants have been reported to be linked to AMD, including CFH Y402H, CFB L9H, C2 E318D, ARMS2 A69S, and HTRA1 G625A. [7] [8] [9] [10] These genetic loci account for only approximately half of the heritability of AMD.
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In an attempt to identify other susceptibility loci, a genome-wide association study 12 (GWAS) revealed a significant relationship between advanced AMD and the hepatic lipase gene (LIPC) (OMIM NG_011465), located on chromosome 15q21. LIPC encodes hepatic triglyceride lipase in the liver and affects high-density lipoprotein cholesterol (HDL-C) levels. 13 Several studies [13] [14] [15] [16] [17] have investigated the relationship between single-nucleotide polymorphisms (SNPs) in the LIPC gene and advanced AMD. The SNP rs10468017 variant (C→T), which is located 514 kilobases upstream of the LIPC gene, is the focus of research interest. However, the results from previous studies are inconsistent, with reports of a significant protective effect of the T allele 13, 15 and reports of no significant relationship. 14, 16, 17 Therefore, we performed a meta-analysis to summarize all relevant evidence for a relationship between LIPC rs10468017 and advanced AMD (CNV or GA) to help us better understand the effect of LIPC on advanced AMD.
Methods

Search Strategy
A comprehensive literature search of PubMed and Embase databases (up to September 15, 2013) was conducted to identify relevant studies. The search strategy comprised the terms macular degeneration, retinal degeneration, retinal neovascularization, choroidal neovascularization, retinal drusen, geographic atrophy, hepatic lipase, and LIPC (more details on the search strategy are available in the eAppendix in the Supplement). No language restrictions were imposed. The titles and abstracts were scanned to exclude any clearly irrelevant studies. The full texts of the remaining articles were read to determine whether they contained information on the topic of interest. To find additional references, we also checked the reference lists of the retrieved publications.
Inclusion Criteria and Data Extraction
Two of us (L.-X.L. and K.-M.H.) independently assessed the retrieved studies and extracted data from each included study.
Any inconsistencies were resolved through discussion. Studies included in the meta-analysis had to fulfill the following criteria: (1) they used a case-control design, (2) advanced AMD was diagnosed using at least 1 eligible method, (3) they reported a measure of the relationship between LIPC and advanced AMD as an odds ratio (OR) with a 95% CI or allowed for calculation of it from raw data contained in the article, and (4) they contained at least 2 comparison groups (a control group and a case group that included patients with advanced AMD [CNV or GA] ). In addition to the first author name and the year of publication, the following information was extracted from each study: study design, sample size, phenotype of the cases evaluated, the mean age and race/ethnicity of the participants, the methods for genotyping and the genotype distributions in cases and controls, and P values for Hardy-Weinberg equilibrium in controls. We contacted the authors of retrieved articles if additional data were needed.
Statistical Analysis
The strength of the relationship between LIPC rs10468017 and advanced AMD was estimated as ORs (95% CIs) under 3 genetic models, namely, an allelic model, a heterozygous model, and a homozygous model. Study-specific ORs were pooled using fixed-effects models with the Mantel-Haenszel method when heterogeneity was negligible or using random-effects models with the DerSimonian-Laird method when heterogeneity was significant. 18 Between-study heterogeneity was assessed using the Cochran Q test and the I 2 statistic. 19 P < .10 was considered statistically significant for the Cochran Q test. I 2 ranges between 0% and 100% (0% represents no heterogeneity), and higher values represent increasing heterogeneity.
We conducted a stratified analysis by advanced AMD subtypes and race/ethnicity. A sensitivity analysis, removing each study one at a time, was performed to confirm the stability of our findings. Publication bias was assessed by the Begg test and the Egger test. 20, 21 The extent of publication bias was also shown with a funnel plot. All statistical analyses were performed using commercially available software (STATA 12.0; StataCorp LP). Except for heterogeneity, P < .05 was considered statistically significant, and all tests were 2-sided.
Results
Search Findings and Study Characteristics
The initial search strategy identified 43 studies from the databases (21 from PubMed and 22 from Embase). After the removal of 19 duplicate publications, 24 studies were considered of potential relevance ( Figure 1 ). In total, 18 articles were retrieved for full-text review, 10 of which met our inclusion criteria. [12] [13] [14] [15] [16] [17] [22] [23] [24] [25] Characteristics of studies included in the metaanalysis are summarized in the Table. Genotype distributions for rs10468017 variant from individual studies are listed in eTable 1 in the Supplement. All studies had a case-control design; 4 of them were a GWAS. Eight studies were performed in participants of white race/ethnicity, and 2 studies were conducted among Asians.
Results of the Meta-analysis
We initially performed a meta-analysis of the relationship between LIPC variant and advanced AMD. The SNP rs10468017 showed a significant summary OR under an allelic model of T vs C (OR, 0.81; 95% CI 0.75-0.88) ( Figure 2 
Sensitivity Analysis
To evaluate the robustness of the relationship between rs10468017 and advanced AMD, we performed a sensitivity analysis by removing each study one at a time and recalculating the summary OR. The pooled OR remained stable under an allelic model, indicating that our results were not influenced by any single study (eTable 2 in the Supplement). This analysis also revealed that 2 studies, by Reynolds et al 25 and
by Yu et al, 22 were the main source of heterogeneity. The I 2 statistics for the ORs decreased from 49.8% to 39.7% (P = .13) after removing the study by Reynolds et al 25 and to 43.1% (P = .10) after removing the study by Yu et al. 22 Low heterogeneity was achieved after removing both studies (I 2 = 20.7%, P = .28), yielding a summary OR of 0.85 (95% CI, 0.80-0.90). The sensitivity analysis also suggested that the significant relationships between rs10468017 and advanced AMD were robust under a heterozygous model and a homozygous model (data not shown).
Publication Bias
We assessed possible publication bias with a funnel plot. Except for the study by Peter et al, 13 all studies were found near the apex of the funnel plot because of the much smaller SEs for ORs under an allelic model (eFigure 3 in the Supplement). Neither the Begg test (P = .27) nor the Egger test (P = .17) suggested publication bias. Also, no publication bias was detected under a heterozygous model (P = .13 for the Begg test and P = .23 for the Egger test) or under a homozygous model (P = .71 for the Begg test and P = .24 for the Begg test).
Discussion
Our meta-analysis showed an allelic summary OR of 0.81 (95% CI, 0.75-0.88) and strongly supported the notion that rs10468017 variant is a protective factor for advanced AMD. 
Source
Lee et al, 15 2013 Peter et al, 13 2011 Cipriani et al, 14 2012 Neale et al, 12 2010 Reynolds et al, 25 2010 Yu et al, 22 2011 Seddon et al, 24 In individuals carrying at least 1 copy of the protective T allele, the risk of advanced AMD decreased by approximately 20%. The pooled ORs were 0.83 and 0.60 under the heterozygous and homozygous models, respectively, suggesting that increased copy number of the T allele lowered the risk of advanced AMD.
Heterogeneity should be considered in meta-analysis interpretation. 26 Our analysis based on the allelic model indicated significant between-study heterogeneity, with an I 2 statistic of 49.8% (P = .05). Compared with noncarriers, the stratified analysis revealed that carriers having at least 1 copy of the protective T allele had approximately 20% (OR, 0.80; 95% CI, 0.74-0.87) and 29% (OR, 0.71; 95% CI, 0.59-0.86) decreased risks of CNV and GA, respectively. A large proportion of the studies were conducted in participants of white race/ethnicity. After exclusion of a study 17 conducted among Asians, the summary OR remained stable. The sensitivity analysis indicated that the studies by Reynolds et al 25 and by Yu et al 22 were the main source of heterogeneity. After excluding these 2 studies, heterogeneity was significantly decreased (I 2 = 20.7%). The summary OR was essentially unchanged in the sensitivity analysis, supporting the reliability of the pooled results.
A strength of our meta-analysis was the large sample size in most of the included studies, especially inclusion of 4 studies of large-scale GWAS design. A sufficient sample size is critical in genetic association studies to achieve adequate statistical power. 27 Several limitations of our meta-analysis should be noted. The analysis was based primarily on unadjusted ORs, without controlling for confounding factors. We cannot address the gene-gene and gene-environment interactions because the original literature provided insufficient information. In our meta-analysis, 5 studies 12,22-25 included participants drawn from the same populations (eg, the Age-Related Eye Disease Study 5 ), which might have affected the pooled results.
However, the sensitivity analysis revealed that these studies did not substantially alter the summary OR or underestimate heterogeneity (data not shown). Until 2010, all genetic variants associated with AMD were identified from candidate gene testing based on the complement factor pathway. 28 Since 2010, several large-scale investigations of GWAS design have identified genes that had not been previously known. 12, 29, 30 LIPC was first reported to be associated with advanced AMD by Neale et al. 12 This finding was replicated in a GWAS 15 but was contradicted by another GWAS. 14 The GWAS by Yu et al 31 was not included in our metaanalysis because the OR under an allelic model was unavailable; however, the OR under an additive genetic model (0, 1, or 2 minor alleles) was 0.84 (P = 2.7 × 10 −12 ) for rs10468017.
Studies focusing on the effects of LIPC on progression to advanced AMD revealed that the T allele of rs10468017 was associated with decreased risk of progression to CNV or GA in the same eye 32, 33 but had no effects on progression to advanced AMD in the second eye. 34 The LIPC gene, which encodes hepatic triglyceride lipase, has an important role in HDL-C metabolism. 35 Highdensity lipoprotein cholesterol transports most of the cholesterol, lutein, and zeaxanthin within the retinal pigment epithelium and Bruch membrane. 12 Inefficiency of cholesterol and carotenoid delivery could lead to deposits, drusen, and stress on the retinal pigment epithelium, which may lead to AMD. 36, 37 However, HDL-C-decreasing alleles of ABCA1 and 
Conclusions
To date, this is the first systematic meta-analysis evaluating the relationship between the LIPC gene variant and advanced AMD. Our analysis provides substantial evidence that LIPC rs10468017 is significantly associated with reduced risk of advanced AMD. This finding expands the number of confirmed AMD susceptibility loci. The LIPC locus may represent another pathway in the pathogenesis of AMD and could lead to insights regarding disease progression, ways to modify the risk of AMD, and novel strategies for AMD treatment.
